PE20191206A1 - Composiciones de aminoacidos y metodos para el tratamiento de enfermedades y trastornos musculares - Google Patents
Composiciones de aminoacidos y metodos para el tratamiento de enfermedades y trastornos muscularesInfo
- Publication number
- PE20191206A1 PE20191206A1 PE2019001282A PE2019001282A PE20191206A1 PE 20191206 A1 PE20191206 A1 PE 20191206A1 PE 2019001282 A PE2019001282 A PE 2019001282A PE 2019001282 A PE2019001282 A PE 2019001282A PE 20191206 A1 PE20191206 A1 PE 20191206A1
- Authority
- PE
- Peru
- Prior art keywords
- amino acid
- entity
- disorders
- treatment
- methods
- Prior art date
Links
- 150000001413 amino acids Chemical class 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 208000037765 diseases and disorders Diseases 0.000 title 1
- 210000003205 muscle Anatomy 0.000 title 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 abstract 2
- 229960004308 acetylcysteine Drugs 0.000 abstract 2
- 239000004475 Arginine Substances 0.000 abstract 1
- 150000008575 L-amino acids Chemical class 0.000 abstract 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 235000020776 essential amino acid Nutrition 0.000 abstract 1
- 239000003797 essential amino acid Substances 0.000 abstract 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 230000003387 muscular Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/316—Foods, ingredients or supplements having a functional effect on health having an effect on regeneration or building of ligaments or muscles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: a) UNA ENTIDAD DE L-AMINOACIDOS DE LEUCINA, UNA ENTIDAD DE R-AMINOACIDOS DE ARGININA Y UNA ENTIDAD DE Q-AMINOACIDOS DE GLUTAMINA; b) UNA ENTIDAD DE N-ACETILCISTEINA (NAC); Y c) UNA ENTIDAD DE AMINOACIDO ESENCIAL (EAA) TAL COMO UNA ENTIDAD DE H-AMINOACIDO HISTIDINA, ENTIDAD DE K-AMINOACIDO LISINA, ENTIDAD DE F-AMINOACIDO FENILALANINA Y ENTIDAD DE T-AMINOACIDO TREONINA; SIEMPRE QUE AL MENOS UNA ENTIDAD DE AMINOACIDOS NO SE PROPORCIONE COMO UN PEPTIDO DE MAS DE 20 RESIDUOS DE AMINOACIDOS DE LARGO; EN DONDE UNA O AMBAS ENTIDADES DE R-AMINOACIDOS Y ENTIDADES DE Q-AMINOACIDOS ESTAN PRESENTES EN UN MAYOR PORCENTAJE EN PESO QUE LA ENTIDAD DE L-AMINOACIDOS. DICHA COMPOSICION ES UTIL PARA MEJORAR LA FUNCION MUSCULAR
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662436073P | 2016-12-19 | 2016-12-19 | |
| US201762443205P | 2017-01-06 | 2017-01-06 | |
| US201762491776P | 2017-04-28 | 2017-04-28 | |
| US201762545358P | 2017-08-14 | 2017-08-14 | |
| US201762576321P | 2017-10-24 | 2017-10-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20191206A1 true PE20191206A1 (es) | 2019-09-10 |
Family
ID=61025047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019001282A PE20191206A1 (es) | 2016-12-19 | 2017-12-19 | Composiciones de aminoacidos y metodos para el tratamiento de enfermedades y trastornos musculares |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20180207119A1 (es) |
| EP (1) | EP3554493A1 (es) |
| JP (1) | JP2020502183A (es) |
| KR (1) | KR20190099243A (es) |
| CN (1) | CN110267655A (es) |
| AU (1) | AU2017379825A1 (es) |
| BR (1) | BR112019012476A2 (es) |
| CA (1) | CA3046558A1 (es) |
| CL (1) | CL2019001685A1 (es) |
| CO (1) | CO2019006292A2 (es) |
| CU (1) | CU20190057A7 (es) |
| EC (1) | ECSP19043725A (es) |
| IL (1) | IL267210A (es) |
| JO (1) | JOP20190147A1 (es) |
| MA (1) | MA50763A (es) |
| MX (1) | MX2019007352A (es) |
| PE (1) | PE20191206A1 (es) |
| PH (1) | PH12019501339A1 (es) |
| TW (1) | TWI780096B (es) |
| WO (1) | WO2018118957A1 (es) |
| ZA (1) | ZA201903581B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
| CN110678172A (zh) | 2017-04-28 | 2020-01-10 | 胺细拉健康公司 | 用于治疗创伤性脑损伤的氨基酸组合物及其使用方法 |
| JP7266581B2 (ja) | 2017-08-14 | 2023-04-28 | アクセラ・ヘルス・インコーポレイテッド | 肝疾患の治療のためのアミノ酸組成物 |
| KR20200040276A (ko) * | 2017-08-14 | 2020-04-17 | 악셀라 헬스 인크. | 신경 손상 치료를 위한 아미노산 조성물 |
| CU20200106A7 (es) | 2018-06-20 | 2021-08-06 | Axcella Health Inc | Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias |
| WO2019246225A1 (en) | 2018-06-20 | 2019-12-26 | Axcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
| EP3810276A1 (en) * | 2018-06-20 | 2021-04-28 | Axcella Health Inc. | Compositions and methods for the reduction or treatment of inflammation |
| MX2020013732A (es) | 2018-06-20 | 2021-02-26 | Axcella Health Inc | Metodos de fabricacion de composiciones de aminoacidos. |
| JP2022501321A (ja) * | 2018-09-27 | 2022-01-06 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | インスリン抵抗性及び／又は糖尿病の予防のための、ヒスチジンとグリシンと他のアミノ酸の使用 |
| CA3142824A1 (en) * | 2019-06-07 | 2020-12-10 | Societe Des Produits Nestle S.A. | Compositions and methods using one or more autophagy-inducing amino acids to potentiate musculoskeletal effect of one or more anabolic amino acids |
| US20220184015A1 (en) * | 2019-06-20 | 2022-06-16 | Societe Des Produits Nestle S.A. | Compositions and methods to potentiate musculoskeletal effect of one or more anabolic amino acids on bone health |
| WO2021060880A1 (ko) * | 2019-09-24 | 2021-04-01 | 마이오텍사이언스 주식회사 | 비천연 아미노산을 함유하는 근감소증의 예방 또는 치료용 약학적 조성물 |
| KR102338447B1 (ko) * | 2019-09-24 | 2021-12-14 | 마이오텍사이언스 주식회사 | 비천연 아미노산을 함유하는 근감소증의 예방 또는 치료용 약학적 조성물 |
| KR102456270B1 (ko) * | 2019-09-24 | 2022-10-19 | 마이오텍사이언스 주식회사 | 비천연 아미노산 유도체를 함유하는 근감소증의 예방 또는 치료용 약학적 조성물 |
| CN110801007A (zh) * | 2019-12-17 | 2020-02-18 | 苟春虎 | 老年肌少症营养肽 |
| WO2021178860A1 (en) * | 2020-03-06 | 2021-09-10 | Axcella Health Inc. | Amino acid compositions and methods for muscle and myotube modulation |
| US20230390234A1 (en) * | 2021-02-26 | 2023-12-07 | Ex Healthcare Inc. | Composition inhibiting muscle loss or promoting muscle formation through skin-derived exosomes |
| CN113288890B (zh) * | 2021-06-21 | 2022-02-22 | 南方医科大学南方医院 | N-乙酰-l-半胱氨酸在制备预防和/或治疗运动损伤的药物中的应用 |
| WO2024026307A1 (en) | 2022-07-25 | 2024-02-01 | Axcella Health Inc. | Biomarker for long covid and fatigue |
| WO2024030909A1 (en) | 2022-08-01 | 2024-02-08 | Axcella Health Inc. | Biomarkers of amino acid composition treatment response in long covid |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2399500A1 (en) * | 2000-02-01 | 2001-08-09 | Muscletech Research And Development Inc. | Alpha lipoic acid based food supplement for increasing lean muscle mass and strength |
| US20040087490A1 (en) * | 2002-09-20 | 2004-05-06 | Troup John P. | Nutritional compositions |
| WO2006009975A2 (en) * | 2004-06-22 | 2006-01-26 | Maxim Pharmaceuticals, Inc. | Histamine to treat disorders affecting muscle function |
| EP1865944B1 (en) * | 2005-03-29 | 2018-08-29 | Ajinomoto Co., Inc. | Amino acid-containing composition used for preventing or remedying decrease in skeletal muscle mass of aged people, comprising L-leucine |
| JP2007023921A (ja) * | 2005-07-19 | 2007-02-01 | Toyota Motor Corp | 内燃機関の制御装置 |
| US20070286909A1 (en) * | 2006-06-07 | 2007-12-13 | Daniel S. Smith | Amino acid compositions |
| CN100518815C (zh) * | 2007-02-15 | 2009-07-29 | 北京苏里曼医药科技有限公司 | 一种氨基酸组合物 |
| MX2014001996A (es) * | 2011-08-19 | 2014-08-29 | Musclepharm Corp | Composiciones y metodos para usarse en promover masa corporal magra. |
| US20170027897A1 (en) * | 2013-10-23 | 2017-02-02 | Whitehead Institute For Biomedical Research | mTORC1 MODULATION BY AMINO ACIDS AND USES THEREOF |
-
2017
- 2017-06-16 JO JOP/2019/0147A patent/JOP20190147A1/ar unknown
- 2017-12-19 MA MA050763A patent/MA50763A/fr unknown
- 2017-12-19 CU CU2019000057A patent/CU20190057A7/es unknown
- 2017-12-19 EP EP17835529.3A patent/EP3554493A1/en not_active Withdrawn
- 2017-12-19 MX MX2019007352A patent/MX2019007352A/es unknown
- 2017-12-19 US US15/847,343 patent/US20180207119A1/en not_active Abandoned
- 2017-12-19 KR KR1020197020658A patent/KR20190099243A/ko not_active Ceased
- 2017-12-19 JP JP2019532941A patent/JP2020502183A/ja active Pending
- 2017-12-19 WO PCT/US2017/067368 patent/WO2018118957A1/en not_active Ceased
- 2017-12-19 TW TW106144666A patent/TWI780096B/zh not_active IP Right Cessation
- 2017-12-19 CN CN201780078594.XA patent/CN110267655A/zh active Pending
- 2017-12-19 PE PE2019001282A patent/PE20191206A1/es unknown
- 2017-12-19 BR BR112019012476A patent/BR112019012476A2/pt not_active IP Right Cessation
- 2017-12-19 CA CA3046558A patent/CA3046558A1/en active Pending
- 2017-12-19 AU AU2017379825A patent/AU2017379825A1/en not_active Abandoned
- 2017-12-29 US US15/858,475 patent/US20180169046A1/en not_active Abandoned
- 2017-12-29 US US15/858,605 patent/US20180169047A1/en not_active Abandoned
-
2019
- 2019-06-04 ZA ZA2019/03581A patent/ZA201903581B/en unknown
- 2019-06-10 IL IL267210A patent/IL267210A/en unknown
- 2019-06-13 PH PH12019501339A patent/PH12019501339A1/en unknown
- 2019-06-17 CO CONC2019/0006292A patent/CO2019006292A2/es unknown
- 2019-06-19 EC ECSENADI201943725A patent/ECSP19043725A/es unknown
- 2019-06-19 CL CL2019001685A patent/CL2019001685A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CU20190057A7 (es) | 2020-02-04 |
| WO2018118957A1 (en) | 2018-06-28 |
| CL2019001685A1 (es) | 2019-08-30 |
| AU2017379825A1 (en) | 2019-06-13 |
| US20180169046A1 (en) | 2018-06-21 |
| US20180207119A1 (en) | 2018-07-26 |
| CN110267655A (zh) | 2019-09-20 |
| JP2020502183A (ja) | 2020-01-23 |
| CO2019006292A2 (es) | 2019-06-28 |
| TW201827068A (zh) | 2018-08-01 |
| IL267210A (en) | 2019-08-29 |
| EP3554493A1 (en) | 2019-10-23 |
| JOP20190147A1 (ar) | 2019-06-18 |
| MA50763A (fr) | 2019-10-23 |
| ZA201903581B (en) | 2020-12-23 |
| US20180169047A1 (en) | 2018-06-21 |
| TWI780096B (zh) | 2022-10-11 |
| CA3046558A1 (en) | 2018-06-28 |
| ECSP19043725A (es) | 2019-07-31 |
| BR112019012476A2 (pt) | 2020-04-14 |
| PH12019501339A1 (en) | 2019-09-30 |
| MX2019007352A (es) | 2019-09-05 |
| KR20190099243A (ko) | 2019-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191206A1 (es) | Composiciones de aminoacidos y metodos para el tratamiento de enfermedades y trastornos musculares | |
| PE20191136A1 (es) | Composiciones de aminoacidos y metodos de tratamiento de enfermedades hepaticas | |
| MX2023009652A (es) | Inhibidores peptidicos de la acumulacion de alfa-sinucleina basados en estructuras. | |
| EA201992247A1 (ru) | Быстрая и контролируемая доставка композиций с восстановленным эффектом антуража | |
| CY1113449T1 (el) | Αντι-ιικες συνθεσεις που περιλαμβανουν γερανιολη και καρβονη | |
| CO6290770A2 (es) | Nuevos derivados de insulina con perfil tiempo/accion extremadamente retardado | |
| UY37998A (es) | Agentes antivirales contra la hepatitis b | |
| CO2020002980A2 (es) | Agentes antivirales contra la hepatitis b. | |
| UY33479A (es) | Compuestos terapeuticos, composicion farmaceutica que lo comprende, metodo de tratamiento y su uso para la manufactura de un medicamento | |
| EA201892007A1 (ru) | 3-дезоксипроизводное и фармацевтические композиции на его основе | |
| BR112013031268A8 (pt) | polipeptídeos | |
| CU20200012A7 (es) | Composiciones de aminoácidos para el tratamiento de enfermedad hepática | |
| CL2018000249A1 (es) | Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h | |
| CL2020001495A1 (es) | Composiciones y método para el tratamiento de enfermedades metabólicas | |
| CY1123040T1 (el) | Συνθεση με βαση αμινοξεα για την αποκατασταση ινο-ελαστινης σε δερματικους συνδετικους ιστους | |
| AR109799A1 (es) | Composición para el tratamiento del cabello | |
| EP3501532A3 (en) | Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof | |
| CL2017003201A1 (es) | Variantes de il-37 | |
| JOP20180127A1 (ar) | صيغ صلبة من منشط محلقة غوانيليل قابل للذوبان (sGC) | |
| BR112017000312A2 (pt) | sistema de tratamento da saúde bucal para a aplicação de fosfato de cálcio amorfo, uso de um ou mais aminoácidos básicos, composição, e uso de um ou mais aminoácidos em um sistema de tratamento da saúde bucal | |
| EA201890590A1 (ru) | Проникающее в мозг производное оксима хромона для терапии леводопа-индуцированной дискинезии | |
| BR112019003915A2 (pt) | composição para tratamento dos cabelos, método de tratamento de cabelo danificado quimicamente e usos de uma composição | |
| MX384262B (es) | Gel intestinal de levodopa y carbidopa y metodos de uso. | |
| BR112019001082A2 (pt) | gel intestinal de levodopa e carbidopa e métodos de uso | |
| MY189021A (en) | Peptides and uses therefor as antiviral agents |